Filing Flows › Cocrystal Pharma (COCP) › Q2 2026
Cocrystal Pharma (COCP) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Cocrystal Pharma (COCP) reported revenue of $105K for the second quarter 2026 (Q2 2026) and -53% from the quarter before.
Cocrystal Pharma, Q2 2026: revenue $105K, net loss $3.2M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $105K | -53% | — |
| Operating profit | −$3.2M | — | — |
| Net earnings | −$3.2M | — | — |
| Operating cash flow | −$2.5M | — | — |
What changed
Revenue was $105K in Q2 2026, down 53% from the previous quarter.
Operating costs exceeded revenue by $3.2M, an operating margin of -3032.4%. The quarter ended with a net loss of $3.2M, wider than the previous quarter's $2.3M loss.
Operating cash flow was −$2.5M. Non-cash charges added back $12K of depreciation and amortization and $92K of share-based compensation. Working capital and other items added $544K.
Questions
What was Cocrystal Pharma's revenue in the second quarter 2026?
Cocrystal Pharma (COCP) reported revenue of $105K for the second quarter 2026 (Q2 2026) and -53% from the quarter before.
Source: Cocrystal Pharma 10-Q on SEC EDGAR.